Document Detail


Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
MedLine Citation:
PMID:  6127744     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.
Authors:
J E Kleinman; D R Weinberger; A Rogol; D J Shiling; W B Mendelson; G C Davis; W E Bunney; R J Wyatt
Related Documents :
7193654 - Prevalence of secondary dapsone resistance in gudiyattam taluk, the leprosy control are...
8888364 - Predicting haloperidol treatment response in chronic schizophrenia.
18452894 - Use of neuromelanin-sensitive mri to distinguish schizophrenic and depressive patients ...
3057814 - Group therapy with schizophrenic patients in outpatient departments.
6429444 - The ph of mitochondria of fibroblasts from a hyperornithinaemia, hyperammonaemia, homoc...
3793914 - Stapling of the knee in juvenile chronic arthritis.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Psychiatry research     Volume:  7     ISSN:  0165-1781     ISO Abbreviation:  Psychiatry Res     Publication Date:  1982 Aug 
Date Detail:
Created Date:  1982-12-18     Completed Date:  1982-12-18     Revised Date:  2008-04-17    
Medline Journal Info:
Nlm Unique ID:  7911385     Medline TA:  Psychiatry Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / therapeutic use
Chronic Disease
Clinical Trials as Topic
Double-Blind Method
Female
Growth Hormone / blood*
Humans
Infusions, Parenteral
Male
Middle Aged
Naloxone / therapeutic use*
Prolactin / blood*
Psychiatric Status Rating Scales
Schizophrenia / blood,  drug therapy*
Schizophrenic Psychology*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 465-65-6/Naloxone; 9002-62-4/Prolactin; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ecology of the bacteria of the sulphur cycle with special reference to anoxic-oxic interface environ...
Next Document:  Prophylactic effect of neuroleptics in symptom-free schizophrenics.